Twynsta · DIN 02371022 · 40 mg & 5 mg · tablet
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Twynsta · DIN 02371022
Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2012-02-29
Health Canada: Marketed since 2011-08-11 · brand TWYNSTA · ATC C09DB04 TELMISARTAN AND AMLODIPINE · form Tablet · route Oral · ingredients TELMISARTAN 40 MG, AMLODIPINE (AMLODIPINE BESYLATE) 5 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Ministry pays: $0.4470 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02371022)
Source record
DIN 02371022: Twynsta
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800296; group id 353; item number 0815; lccId None; manufacturer id BOE
Source form: Tab; strength: 40mg & 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.8481; ministry $0.4470
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02371022
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85622
Interchangeable products
Riva-Telmisartan / Amlodipine · DIN 02559854 · $0.4470
Shortage status: not checked (no credentials)